Australia Pulmonary Arterial Hypertension Market Size & Outlook
Australia pulmonary arterial hypertension market, 2018-2030 (US$M)
Related Markets
Australia pulmonary arterial hypertension market highlights
- The Australia pulmonary arterial hypertension market generated a revenue of USD 122.5 million in 2023 and is expected to reach USD 195.0 million by 2030.
- The Australia market is expected to grow at a CAGR of 6.9% from 2024 to 2030.
- In terms of segment, prostacyclin and prostacyclin analogs was the largest revenue generating drug class in 2023.
- SGC Stimulators is the most lucrative drug class segment registering the fastest growth during the forecast period.
Pulmonary arterial hypertension market data book summary
| Market revenue in 2023 | USD 122.5 million |
| Market revenue in 2030 | USD 195.0 million |
| Growth rate | 6.9% (CAGR from 2023 to 2030) |
| Largest segment | Prostacyclin and prostacyclin analogs |
| Fastest growing segment | SGC Stimulators |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Endothelin Receptor Antagonists (ERAs), PDE-5 Inhibitors, Prostacyclin and Prostacyclin Analogs, SGC Stimulators |
| Key market players worldwide | United Therapeutics Corp, Bayer AG, Gilead Sciences Inc, Johnson & Johnson, Viatris Inc, GlaxoSmithKline, Sandoz Group AG ADR, Lupin, Sun Pharmaceutical Industries, Teva Pharmaceutical Industries Ltd |
Other key industry trends
- In terms of revenue, Australia accounted for 1.7% of the global pulmonary arterial hypertension market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, Japan pulmonary arterial hypertension market is projected to lead the regional market in terms of revenue in 2030.
- South Korea is the fastest growing regional market in Asia Pacific and is projected to reach USD 191.4 million by 2030.
Prostacyclin and prostacyclin analogs was the largest segment with a revenue share of 47.76% in 2023. Horizon Databook has segmented the Australia pulmonary arterial hypertension market based on endothelin receptor antagonists (eras), pde-5 inhibitors, prostacyclin and prostacyclin analogs, sgc stimulators covering the revenue growth of each sub-segment from 2018 to 2030.
The PAH market in Australia is growing in a steady speed during the forecast period. Australian government is initiative by subsidizing for the treatment of PAH in Australia in order to curb the diseases burden.
For instance, under section 100 of the National Health Act 1953 through the Pharmaceutical Benefits Scheme using the following agents for the treatment of PAH are subsidized such as: Bosentan Monohydrate, Epoprostenol Sodium, Iloprost Trometamol, Macitentan, Riociguat, Sildenafil Citrate, Tadalafil, and Ambrisentan From February 2021, Uptravi is expected to be listed on the Pharmaceutical Benefits Scheme (PBS) for the first time, to treat PAH for use in grouping with existing PAH therapies.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Pulmonary Arterial Hypertension Market Scope
Pulmonary Arterial Hypertension Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Australia pulmonary arterial hypertension market size, by drug class, 2018-2030 (US$M)
Australia Pulmonary Arterial Hypertension Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
